University of Alabama at Birmingham.
Blood. 2018 Feb 8;131(6):589-590. doi: 10.1182/blood-2017-12-819011.
In this issue of , Green et al identified an innovative and promising pretargeted radioimmunotherapy (RIT) approach for the treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma. Pretargeted RIT of B-cell malignancies with a CD38 bispecific monoclonal antibody (mAb) is a novel approach, and the results achieved in preclinical models are very impressive. CD38 is an excellent target because it has high density and stable expression in multiple myeloma and NHL.
本期 ，Green 等人提出了一种创新性且有前景的用于治疗非霍奇金淋巴瘤（NHL）和多发性骨髓瘤的靶向放射性免疫疗法（RIT）方法。用 CD38 双特异性单克隆抗体（mAb）进行 B 细胞恶性肿瘤的靶向 RIT 是一种新方法，在临床前模型中取得的结果令人非常印象深刻。CD38 是一个极好的靶点，因为它在多发性骨髓瘤和 NHL 中具有高密度和稳定的表达。
